Cover Image
市場調查報告書

HPAPI、細胞毒性藥的製造市場 (2016-2026年):第2版

HPAPIs and Cytotoxic Drugs Manufacturing Market 2016-2026 (2nd Edition)

出版商 ROOTS ANALYSIS 商品編碼 310060
出版日期 內容資訊 英文 345 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
HPAPI、細胞毒性藥的製造市場 (2016-2026年):第2版 HPAPIs and Cytotoxic Drugs Manufacturing Market 2016-2026 (2nd Edition)
出版日期: 2016年03月09日 內容資訊: 英文 345 Pages
簡介

本報告提供急速成長的HPAPI、細胞毒性藥的製造市場相關調查,HPAPI及細胞毒性藥定義和概要,從事HPAPI、細胞毒性藥製造的CMO的製造能力,產業規模,職業暴露限值 (OEL),設備的定位,大醫藥品經營者公司內部開發能力,經營模式的案例研究,SWOT分析,企業策略,主要CMO簡介等彙整資料。

第1章 序文

第2章 摘要整理

第3章 簡介

  • 背景
  • HPAPI:定義
  • 細胞毒性藥:定義
  • 醫藥品產業上CMO所扮演的角色

第4章 市場概要

  • 本章概要
  • HPAPI/細胞毒性藥廠商
  • 公司內部能力
  • 法規形勢

第5章 HPAPI製造市場

  • 本章概要
  • HPAPI能力分析
    • 各產業規模分析
    • 地區分析
  • 各職業暴露限度(OEL)分析
  • CMO的製造能力
    • Aesica Pharmaceuticals
    • Ajinomoto Omnichem
    • Ampac Fine Chemicals (AFC)
    • Aptuit
    • Asymchem Laboratories
    • AVANTHERA
    • Cambrex
    • Cerbios
    • CordenPharma
    • Farmabios
    • Helsinn Advanced Synthesis
    • IRIX Pharmaceuticals
    • FineTech Pharmaceuticals
    • Pfanstiehl
    • Syntagon

第6章 細胞毒性藥製造市場

  • 本章概要
  • 細胞毒性藥能力分析
  • 地區分析
    • 各產業規模分析
    • 地區分析
    • 職業暴露限度(OEL)分別分析
    • 菲爾&結束能力分析

第7章 代表案例:「一站式服務」

  • 簡介
  • 案例研究
  • Albany Molecular Research
  • Baxter BioPharma Solutions
  • CordenPharma
  • Fareva
  • Pierre Fabre Laboratories

第8章 市場規模、預測

  • 本章概要
  • 預測手法
  • 細胞毒性藥製造市場
  • HPAPI委託製造市場

第9章 美國的主要CMO

第10章 EU的主要CMO

第11章 亞太地區的主要CMO

第12章 新興CMO

第13章 近幾年的發展

  • 本章概要
  • 由於CMO的投資:新設施的建設、擴張
  • 契約、聯盟

第14章 SWOT分析

  • 本章概要
  • 優勢
  • 弱點
  • 機會
  • 威脅

第15章 代表案例:ADC的委託製造

  • 背景
  • ADC藥:有限的技術供應商
  • ADC製造的階段
  • ADC製造的課題
  • ADC公司內部製造
  • 全球委託製造的存在感
  • 投資的潛力
  • 新興企業的出現
  • ADC能力提供的委託製造業者的合作
  • CMO的製造連接試劑
  • 有HPAPI/細胞毒性藥的製造能力的CMO
  • konjugeto能力的擴大
  • ADC的全方位服務供應商和未滿足需求

第16章 採訪

第17章 總論

第18章 附錄I:圖表資料

第19章 附錄II:企業清單

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: RA10056

With the rising demand for targeted therapies, high potency compounds such as high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs have become the key focus of researchers and manufacturers worldwide. HPAPIs, which include cytotoxic APIs, are drug substances that are formulated to manufacture high potency drug products. Cytotoxic drugs are a category of highly potent drug products and, due to their increased utility in the treatment of cancer indications, have gained wide attention in recent years.

Some of the key benefits of these compounds include low dosage requirement and lower side effects. With over 25% of the total drugs worldwide being classified as highly potent, the HPAPI market is currently cited as one of the most important segments of pharmaceutical industry. The market is currently dominated by contract manufacturers. Though some pharmaceutical companies have invested in building in-house capabilities, the capital intensive nature and specialized containment requirements make the role of contract manufacturers crucial. SAFC, Lonza and Evonik are amongst the pioneers in the field of manufacturing highly potent compounds. In addition, new entrants such as Labochim, Medichem, OPKO Health, Project Pharmaceutics, Regis Technologies, ScinoPharm and Wuxi Pharma have also recently sprung up.

The growing number of investments and partnerships in this field are evident of the current market intensity. Majority of the investments in recent years have been expansion programs highlighting that manufacturers are keen to expand their existing production facilities to meet the growing demand. Looking at the ongoing focus, we certainly believe that stakeholders will continue to invest in this area. The current market landscape will gradually evolve as manufacturers look to gain competitive advantage in the near future.

Synopsis:

The ‘HPAPIs and Cytotoxic Drugs Manufacturing Market, 2016-2026 (2nd edition)' report provides an extensive study of the rapidly growing manufacturing market of HPAPIs and cytotoxic drugs. Due to their numerous advantages and widespread application in treatment of cancer and other disorders, HPAPIs and cytotoxics have emerged as one of the key focus areas of researchers across the globe. When compared to conventional therapeutic products, these compounds offer multiple advantages including low dosage requirements, low cost and high target specificity. The focus of this report is primarily to understand the current competitive landscape and the likely future evolution of both the HPAPIs and cytotoxic drugs market over the next decade. Amongst other elements, the report covers the following aspects:

  • Review of the manufacturing sites of various CMOs involved in HPAPIs / cytotoxic drugs manufacturing.
  • Overview of the pharmaceutical companies with in-house manufacturing capabilities.
  • Investments in the expansion or for setting up of new facilities as well as collaborations that have taken place in the recent past.
  • A detailed case study on the manufacturing of antibody drug conjugates (ADCs), one of the well-known emerging classes of cytotoxic drugs.

Though some pharmaceutical companies have in-house capabilities, the development of HPAPIs / cytotoxic drugs is primarily outsourced to contract manufacturers. The future growth of this market is likely to be driven by the increasing demand for oncology drugs, as majority of high potency and cytotoxic drugs are being developed for the treatment of cancer. As this segment continues to evolve, the use of HPAPIs and cytotoxic drugs in other therapeutic areas such as glaucoma, hormonal imbalances and respiratory disorders are also being investigated.

Despite their benefits and the scope of a promising future, the study also highlights that there are considerable challenges associated with the production of these compounds. Due to their highly toxic nature, they pose significant occupational hazards, if not handled carefully. In addition, cross-contamination with other products can be highly detrimental for the patients. Therefore, adequate containment strategies and a proper classification of hazards is essential for the uptake of this market.

The base year for this report is 2015; actual sales data of respective companies has been presented for up to last five years. The report provides market forecasts for the period 2016 - 2026. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from secondary and primary research.

Example Highlights:

  • 1. Oncology is the key driver behind the growth of HPAPIs and cytotoxic drugs. Around 60% of the HPAPIs are being developed for the treatment of cancer. The trend is likely to continue and the anti-cancer market will sustain the growth of HPAPIs and cytotoxics in the future.
  • 2. CMOs are the key stakeholders in the market as a good proportion of HPAPI / cytotoxics manufacturing is currently outsourced due to stringent manufacturing protocols and safety requirements. During our research, we identified 96 CMOs (with over 130 production facilities worldwide) that are focused in this area; approximately 40% of these facilities are dedicated to manufacturing of both HPAPIs and cytotoxic drugs.
  • 3. The market is highly fragmented; companies such as Capsugel, Idifarma, Labochim, Medichem, OPKO Health, ScinoPharm, WuXi PharmaTech are some of the new entrants in this market that have recently expanded their service portfolio. Having said this, established pharma companies such as Roche, Merck, GSK, BMS and Boehringer Ingelheim have also established in-house capabilities.
  • 4. Over 15% CMOs have established one-stop-shop model to provide manufacturing services for both HPAPI and finished cytotoxic drugs. Examples include AbbVie, AMRI, Baxter BioPharma Solutions, CordenPharma and Fareva.
  • 5. North America and Europe are the predominant regions where HPAPI and cytotoxic drugs production facilities are located. The US accounts for around 23% of the total HPAPI production facilities followed by Italy (13%) and Switzerland (11%). In the case of cytotoxic drugs, 30% of production facilities are located in the US; this is followed by Germany (14%) and the UK (10%). Companies have also moved their focus to developing countries such as China and India in order to take advantage of relatively lower costs.
  • 6. Several collaborations have been recently inked between stakeholders with an aim to combine their manufacturing expertise. Of the 50 partnerships we studied during our research, an overwhelming proportion were acquisitions (55%) and manufacturing collaborations (38%).
  • 7. Catering to the wider demand, several CMOs have regularly engaged in investment programs to expand their production set ups. Since 2006, there have been more than 100 investments to add new facilities and / or to expand existing capacities; SAFC has led this activity followed by Novasep, Aesica Pharmaceuticals, CARBOGEN AMCIS, Lonza, Piramal, Helsinn and Baxter BioPharma Solutions.
  • 8. Overall, the HPAPI and cytotoxic drugs market holds enormous potential for the contract manufacturers. We anticipate this opportunity for the CMOs to grow at an annualized rate of ~10% over the next ten years. North American and Western European CMOs will continue to dominate with a share of over 70% in the overall market. Developing countries, such as India and China, are likely to emerge with a share of around 13% by 2026.

Research Methodology:

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market is likely to evolve across different geographical regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The various secondary sources of information that we use include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the key insights captured in our research. The summary offers a high-level view on the likely evolution of the contract manufacturing market for HPAPIs and cytotoxic drugs.

Chapter 3 provides a general introduction to HPAPIs and cytotoxic drugs. In this chapter, we have also explained, in detail, specific containment requirements for handling HPAPIs and cytotoxic drugs.

Chapter 4 identifies the contract manufacturers actively involved in the HPAPIs / cytotoxic drugs market. The chapter also provides details on various aspects related to these CMOs including their production capabilities, scale of operation, occupational exposure limits (OELs) and the geographic location of their facilities. It also highlights the leading pharmaceutical companies that have in-house capabilities for developing HPAPIs / cytotoxic drugs. In addition, the chapter provides a comprehensive overview of the current regulatory landscape governing this segment of the industry.

Chapter 5 provides a detailed analysis of the various CMOs involved in the manufacturing of HPAPIs. The chapter presents an in-depth comparative analysis of the major players in this segment based on regional distribution, scale of operation and OELs. The chapter also highlights the production specifications of the leading manufacturers in the market.

Chapter 6 provides a detailed analysis of the CMOs involved in the manufacturing of cytotoxic drugs. In addition to regional distribution of these organizations, the chapter presents a comprehensive review of various other parameters related to their capabilities such as scale of operation, OELs and fill / finish.

Chapter 7 introduces the one-stop-shop model with respect to HPAPIs / cytotoxic drugs manufacturing. The chapter includes case studies of five leading companies: AMRI, Baxter BioPharma Solutions, CordenPharma, Fareva and Pierre Fabre Laboratories that are operating as one-stop-shops.

Chapter 8 presents our forecast for both HPAPIs and cytotoxic drugs contract manufacturing market. All our predictions related to this market's future have been backed up by robust analysis of data procured from both secondary and primary sources. Due to the uncertain nature of the market, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios. The chapter also presents a region-wise market forecast for both HPAPIs and cytotoxic drugs contract manufacturing.

Chapter 9 contains detailed profiles of key CMOs, located in the US, that are involved in the manufacturing of HPAPIs and cytotoxic drugs. Each profile includes information such as the company's geographical presence, its financial performance, manufacturing capabilities, investments and partnerships.

Chapter 10 provides detailed profiles of key CMOs, located in Europe, that are involved in the manufacturing of HPAPIs and cytotoxic drugs. Similar to chapter 9, each profile includes information on the company's geographical presence, its financial performance, manufacturing capabilities, investments and partnerships.

Chapter 11 provides detailed profiles of key CMOs that provide manufacturing services for HPAPIs and cytotoxic drugs in the Asia Pacific region. Similar to the earlier two chapters, each company profile includes information on the company's geographical presence, its financial performance, manufacturing capabilities, investments and partnerships.

Chapter 12 provides profiles of several emerging CMOs in the HPAPIs and cytotoxic drugs manufacturing market. As in the earlier chapters, each profile contains information on the company's geographical presence, financial performance (where available), manufacturing capabilities, investments and partnerships.

Chapter 13 analyzes the recent developments in the HPAPIs / cytotoxic drugs manufacturing market. This chapter contains information on the investments that have been made and the various partnerships that have been established in the past few years. It also presents an analysis of how the market has evolved over the years. In addition, the chapter contains a brief section on how recent technological advancements have led to the market's evolution.

Chapter 14 provides a SWOT analysis capturing the key elements that are likely to influence future growth in this market.

Chapter 15 presents a case study on antibody drug conjugates (ADCs) manufacturing market; ADCs represent one of the rapidly expanding segments of biopharmaceutical industry and are expected to emerge as a significant opportunity for the CMOs in near future. The case study contains detailed information on both in-house and contract manufacturing in the ADC market.

Chapter 16 is a collection of transcripts of interviews conducted during the course of this study. The senior people interviewed for this study were Antonella Mancuso, Vice President & Chief Operating Officer and Maria Elena Guadagno, Business Director (BSP Pharmaceuticals), Stacy McDonald, Group Product Manager & Jennifer L. Mitcham, Director - Business Development (Catalent Pharma Solutions), Roberto Margarita, Business Development Director (CordenPharma), Allison Vavala, Senior Manager, Business Development (Helsinn), Javier E. Aznárez Araiz, Business Development (Idifarma), Mark Wright, Site Head, Grangemouth (Piramal Healthcare) and Klaus Hellerbrand, Managing Director (ProJect Pharmaceutics). In addition to detailed interviews, we had also conducted a comprehensive survey to learn more about the manufacturing capabilities / capacities of various stakeholders in the industry.

Chapter 17 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in the previous chapters.

Chapter 18 is an appendix that provides tabulated data for all the figures provided in the report.

Chapter 19 is an appendix that provides a list of companies and organizations mentioned in the report.

Table of Contents

1. Preface

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. Executive Summary

3. Introduction

  • 3.1. Context and Background
  • 3.2. HPAPIs: Definition
    • 3.2.1. Containment Measures
    • 3.2.2. Classification of HPAPIs
  • 3.3. Cytotoxic Drugs: Definition
    • 3.3.1. Containment Measures
  • 3.4. Role of CMOs in the Pharmaceutical Industry
    • 3.4.1. Contract Manufacturing in HPAPIs and Cytotoxic Drugs

4. Market Overview

  • 4.1. Chapter Overview
  • 4.2. HPAPIs / Cytotoxic Drugs Manufacturers
  • 4.3. In-house Capabilities
  • 4.4. Regulatory Landscape

5. HPAPI Manufacturing Market

  • 5.1. Chapter Overview
  • 5.2. HPAPI Capability Analysis
    • 5.2.1. Analysis by Scale of Operation
    • 5.2.2. Regional Analysis
      • 5.2.2.1. Laboratory Scale
      • 5.2.2.2. Development Scale
      • 5.2.2.3. Commercial/Industrial Scale
      • 5.2.2.4. Regional Distribution
    • 5.2.3. Analysis by Occupational Exposure Limit (OEL)
  • 5.3. CMOs: Production Capabilities
    • 5.3.1. Aesica Pharmaceuticals
    • 5.3.2. Ajinomoto Omnichem
    • 5.3.3. Ampac Fine Chemicals (AFC)
    • 5.3.4. Aptuit
    • 5.3.5. Asymchem Laboratories
    • 5.3.6. AVANTHERA
    • 5.3.7. Cambrex
    • 5.3.8. Cerbios
    • 5.3.9. CordenPharma
    • 5.3.10. Farmabios
    • 5.3.11. Helsinn Advanced Synthesis
    • 5.3.12. IRIX Pharmaceuticals
    • 5.3.13. FineTech Pharmaceuticals
    • 5.3.14. Pfanstiehl
    • 5.3.15. Syntagon

6. Cytotoxic Drugs Manufacturing Market

  • 6.1. Chapter Overview
  • 6.2. Cytotoxics Capability Analysis
    • 6.2.1. Analysis by Scale of Operation
    • 6.2.2. Regional Analysis
      • 6.2.2.1. Laboratory Scale
      • 6.2.2.2. Development Scale
      • 6.2.2.3. Commercial / Industrial Scale
      • 6.2.2.4. Regional Distribution
    • 6.2.3. Analysis by Operational Exposure Limits (OEL)
    • 6.2.4. Fill / Finish Capability Analysis

7. Case In Point: The ‘One-Stop-Shops'

  • 7.1. Introduction
  • 7.2. Case Studies
  • 7.3. Albany Molecular Research (AMRI Global)
    • 7.3.1. Introduction
    • 7.3.2. Financial Performance
    • 7.3.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 7.3.4. Manufacturing Experience
    • 7.3.5. Recent Developments
  • 7.4. Baxter BioPharma Solutions (Business Unit of Baxter International)
    • 7.4.1. Introduction
    • 7.4.2. Financial Performance
    • 7.4.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 7.4.4. Recent Developments
  • 7.5. CordenPharma
    • 7.5.1. Introduction
    • 7.5.2. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 7.5.3. Recent Developments
  • 7.6. Fareva
    • 7.6.1. Introduction
    • 7.6.2. Financial Performance
    • 7.6.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 7.6.4. Manufacturing Experience
    • 7.6.5. Recent Developments
  • 7.7. Pierre Fabre Laboratories
    • 7.7.1. Introduction
    • 7.7.2. Financial Performance
    • 7.7.3. Pierre Fabre Medicament Production (PFMP) / Aquitaine Pharm International
    • 7.7.4. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 7.7.5. Manufacturing Experience
    • 7.7.6. Recent Developments

8. Market Size and Forecast

  • 8.1. Chapter Overview
  • 8.2. Forecast Methodology
  • 8.3. Cytotoxic Drugs Manufacturing Market, 2016- 2026
    • 8.3.1. Overall Market Forecast
    • 8.3.2. Regional Market Forecast
  • 8.4. HPAPIs Manufacturing Market, 2016- 2026
    • 8.4.1. Overall Market Forecast
    • 8.4.2. Regional Market Forecast

9. Leading CMOs in the US

  • 9.1. Chapter Overview
  • 9.2. AbbVie (Abbott Contract Manufacturing)
    • 9.2.1. Introduction
    • 9.2.2. Financial Performance
    • 9.2.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 9.2.4. Manufacturing Experience
    • 9.2.5. Recent Developments
  • 9.3. Catalent Pharma Solutions
    • 9.3.1. Introduction
    • 9.3.2. Financial Performance
    • 9.3.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 9.3.4. Recent Developments
  • 9.4. Evonik
    • 9.4.1. Introduction
    • 9.4.2. Financial Performance
    • 9.4.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 9.4.4. Recent Developments
  • 9.5. Pfanstiehl
    • 9.5.1. Introduction
    • 9.5.2. Financial Performance
    • 9.5.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 9.5.4. Recent Developments
  • 9.6. Sigma-Aldrich Fine Chemicals (SAFC)
    • 9.6.1. Introduction
    • 9.6.2. Financial Performance
    • 9.6.3. SAFC Commercial: The Contract Manufacturer
    • 9.6.4. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 9.6.5. Manufacturing Experience
    • 9.6.6. Recent Developments

10. Leading CMOs in the EU

  • 10.1. Chapter Overview
  • 10.2. BSP Pharmaceuticals
    • 10.2.1. Introduction
    • 10.2.2. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 10.2.3. Manufacturing Experience
    • 10.2.4. Recent Developments
  • 10.3. CARBOGEN AMCIS
    • 10.3.1. Introduction
    • 10.3.2. Financial Performance
    • 10.3.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 10.3.4. Recent Developments
  • 10.4. Helsinn Advanced Synthesis (Division of Helsinn Group)
    • 10.4.1. Introduction
    • 10.4.2. Financial Performance
    • 10.4.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 10.4.4. Manufacturing Experience
    • 10.4.5. Recent Developments
  • 10.5. Lonza
    • 10.5.1. Introduction
    • 10.5.2. Financial Performance
    • 10.5.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 10.5.4. Classification System by Lonza
    • 10.5.5. Manufacturing Experience
    • 10.5.6. Recent Developments
  • 10.6. Novasep
    • 10.6.1. Introduction
    • 10.6.2. Financial Performance
    • 10.6.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 10.6.4. Manufacturing Experience
    • 10.6.5. Recent Developments
  • 10.7. Pfizer CentreSource
    • 10.7.1. Introduction
    • 10.7.2. Financial Performance
    • 10.7.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
  • 10.8. Piramal Healthcare Pharma Solutions
    • 10.8.1. Introduction
    • 10.8.2. Financial Performance
    • 10.8.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 10.8.4. Manufacturing Experience
    • 10.8.5. Recent Developments
  • 10.9. TAPI (Teva Active Pharmaceutical Ingredients)
    • 10.9.1. Introduction
    • 10.9.2. Financial Performance
    • 10.9.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities

11. Leading CMOs in Asia Pacific

  • 11.1. Chapter Overview
  • 11.2. Dr. Reddy's Laboratories (Custom Pharmaceutical Services)
    • 11.2.1. Introduction
    • 11.2.2. Financial Performance
    • 11.2.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 11.2.4. Recent Developments
  • 11.3. IDT Australia
    • 11.3.1. Introduction
    • 11.3.2. Financial Performance
    • 11.3.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 11.3.4. Recent Developments
  • 11.4. Intas Pharmaceuticals
    • 11.4.1. Introduction
    • 11.4.2. Financial Performance
    • 11.4.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 11.4.4. Recent Developments

12. Emerging CMOs

  • 12.1. Chapter Overview
  • 12.2. Capsugel
    • 12.2.1. Introduction
    • 12.2.2. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 12.2.3. Recent Developments
  • 12.3. Formosa Laboratories
    • 12.3.1. Introduction
    • 12.3.2. Financial Performance
    • 12.3.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 12.3.4. Recent Developments
  • 12.4. Icrom
    • 12.4.1. Introduction
    • 12.4.2. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
  • 12.5. Idifarma
    • 12.5.1. Introduction
    • 12.5.2. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 12.5.3. Recent Developments
  • 12.6. Infa Group
    • 12.6.1. Introduction
    • 12.6.2. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 12.6.3. Recent Developments
  • 12.7. Medichem
    • 12.7.1. Introduction
    • 12.7.2. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 12.7.3. Recent Developments
  • 12.8. NerPharMa
    • 12.8.1. Introduction
    • 12.8.2. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 12.8.3. Recent Developments
  • 12.9. OPKO Health
    • 12.9.1. Introduction
    • 12.9.2. Financial Performance
    • 12.9.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 12.9.4. Recent Developments
  • 12.10. ProJect Pharmaceutics
    • 12.10.1. Introduction
    • 12.10.2. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
  • 12.11. Regis Technologies
    • 12.11.1. Introduction
    • 12.11.2. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
  • 12.12. ScinoPharm
    • 12.12.1. Introduction
    • 12.12.2. Financial Performance
    • 12.12.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities
    • 12.12.4. Recent Developments
  • 12.13. SynTheAll Pharmaceutical Co. (Manufacturing Subsidiary of WuXi AppTec)
    • 12.13.1. Introduction
    • 12.13.2. Financial Performance
    • 12.13.3. HPAPIs and / or Cytotoxic Drugs Manufacturing Facilities

13. Recent Developments

  • 13.1. Chapter Overview
  • 13.2. Investments by CMOs: Establishment of New Facilities and Facility Expansions
    • 13.2.1. Growing Number of Investments over the Years
    • 13.2.2. Sigma Aldrich Fine Chemicals Leads the Investments Activity
  • 13.3. Deals and Partnerships
    • 13.3.1. Analysis by Type of Partnership
    • 13.3.2. Analysis by Year of Partnership

14. SWOT Analysis

  • 14.1. Chapter Overview
  • 14.2. Strengths
    • 14.2.1. Advantages of HPAPIs and Cytotoxics
    • 14.2.2. Ongoing Focus from Leading Pharmaceutical Companies
  • 14.3. Weaknesses
    • 14.3.1. Lack of a Universal System of Classification
    • 14.3.2. Occupational Hazards
    • 14.3.3. Cross-contamination Risks
    • 14.3.4. High Cost Involved in Production
  • 14.4. Opportunities
    • 14.4.1. Technological Advancements
      • 14.4.1.1. Prospects for Single-use Systems in High potency/ Cytotoxics manufacturing
      • 14.4.1.2. Continuous Flow Processing
    • 14.4.2. Growing Opportunities for CMOs
  • 14.5. Threats
    • 14.5.1. Regional Reforms in Drug Pricing and Reimbursement Policies
    • 14.5.2. In-House Manufacturing

15. Case in Point: Contract Manufacturing in ADCs

  • 15.1. Background
  • 15.2. ADC Drugs: Limited Technology Providers
  • 15.3. ADC Manufacturing: Key Steps
  • 15.4. ADC Manufacturing: Key Challenges
  • 15.5. In-House Manufacturing of ADCs
  • 15.6. Global Presence of Contract Manufacturers
  • 15.7. A Promising Scope for Investment
  • 15.8. Emergence of Start-Ups
  • 15.9. Contract Manufacturers Collaborating to Provide ADC Capabilities
  • 15.10. CMOs Manufacturing Linkers
  • 15.11. CMOs with HPAPI / Cytotoxic Manufacturing Capabilities
  • 15.12. Growing Conjugation Capability
  • 15.13. Full Service Providers for ADCs: An Unmet Need

16. Interview Transcripts

  • 16.1. Chapter Overview
  • 16.2. Javier E. Aznàrez Araiz, Business Development, Idifarma Desarrollo Farmacéutico
  • 16.3. Klaus Hellerbrand, Managing Director, ProJect Pharmaceutics
  • 16.4 Antonella Mancuso, Vice President & Chief Operating Officer; Maria Elena Guadagno, Business Director, BSP Pharmaceuticals
  • 16.5. Mark Wright, Site Head, Grangemouth, Piramal Healthcare
  • 16.6. Roberto Margarita, Business Development Director, CordenPharma
  • 16.7. Allison Vavala, Senior Manager, Business Development, Helsinn
  • 16.8. Stacy McDonald, Group Product Manager & Jennifer L. Mitcham, Director - Business Development, Catalent Pharma Solutions

17. Conclusion

  • 17.1. Oncological Indications are Likely to Continue to Generate the Maximum Demand for HPAPIs and Cytotoxic Drugs
  • 17.2. Multiple Drivers to Result in a Healthy Growth Rate
  • 17.3. CMOs Likely to Play a Pivotal Role in the Market's Evolution
  • 17.4. US and Europe to Remain as the Key Manufacturing Hubs
  • 17.5. A Multi-billion Dollar Rapidly Expanding Market
  • 17.6. Concluding Remarks

18 Appendix 1: Tabulated Data

19. Appendix 2: List of Companies and Organizations

List of Figures

  • Figure 3.1: OEB System: International Safety Systems
  • Figure 3.2: HPAPIs: Different Forms
  • Figure 5.1: HPAPI Production Facilities: Distribution by Scale of Operation
  • Figure 5.2: HPAPI CMOs: Regional Presence (Laboratory Scale)
  • Figure 5.3: HPAPI CMOs: Regional Presence (Development Scale)
  • Figure 5.4: HPAPI CMOs: Regional Presence (Commercial / Industrial Scale)
  • Figure 5.5: HPAPI Production Facilities: Regional Distribution
  • Figure 6.1: Cytotoxic Drugs Production Facilities: Distribution by Scale of Operation
  • Figure 6.2: Cytotoxic Drugs CMOs: Regional Presence (Laboratory Scale)
  • Figure 6.3: Cytotoxic Drugs CMOs: Regional Presence (Development Scale)
  • Figure 6.4: Cytotoxic Drugs CMOs: Regional Presence (Commercial / Industrial Scale)
  • Figure 6.5: Cytotoxic Drugs Production Facilities: Regional Distribution
  • Figure 7.1: AMRI Global: Contract Revenues (USD Million), FY 2010 - H1 2015
  • Figure 7.2: AMRI Global: Segment Revenues (USD Million), FY 2014
  • Figure 7.3: AMRI Global: Segment Contract Revenues (USD Million), H1 2014 & H1 2015
  • Figure 7.4: Baxter BioPharma Solutions: Service Portfolio
  • Figure 7.5: Baxter BioPharma Solutions: Revenues (USD Million), FY 2011 - FY 2014
  • Figure 7.6: Pierre Fabre Laboratories: Revenues (EUR Million), FY 2014
  • Figure 8.1: Cytotoxic Drugs Sales Forecast, 2016 - 2026: Base Scenario (USD Billion)
  • Figure 8.2: Cytotoxic Drugs Contract Manufacturing Market, 2016 - 2026: Base Scenario (USD Billion)
  • Figure 8.3: Cytotoxic Drugs Contract Manufacturing Market: Regional Distribution, 2016, 2021 and 2026
  • Figure 8.4: HPAPIs Contract Manufacturing Market, 2016 - 2026: Base Scenario (USD Billion)
  • Figure 8.5: HPAPI Contract Manufacturing Market: Regional Distribution, 2016, 2021 and 2026
  • Figure 9.1: AbbVie: Revenues (USD Billion), FY 2010 - H1 2015
  • Figure 9.2: Catalent Pharma Solutions: Revenues (USD Billion), FY 2010 - H1 2016
  • Figure 9.3: Catalent Pharma Solutions: Segment Revenues (USD Million), FY 2015
  • Figure 9.4: Evonik: Revenues (EUR Billion), FY 2010 - H1 2015
  • Figure 9.5: Evonik: Segment Revenues (EUR Billion), FY 2014
  • Figure 9.6: Sigma-Aldrich: Revenues (USD Billion), FY 2010 - H1 2015
  • Figure 9.7: Sigma-Aldrich: Segment Revenues (USD Million), FY 2014
  • Figure 9.8: Sigma-Aldrich: Segment Revenues (USD Million), Q1 - Q3 2015
  • Figure 9.9: SAFC Commercial: Revenues (USD Million)
  • Figure 10.1: Dishman Group: Turnover (INR Billion), FY 2010 - H1 2016
  • Figure 10.2: Dishman Group: Segment Revenues (INR Billion), FY 2015
  • Figure 10.3: CARBOGEN AMCIS: Revenues (INR Billion), FY 2011 - FY 2015
  • Figure 10.4: Lonza: Revenues (CHF Billion), FY 2010 - H1 2015
  • Figure 10.5: Lonza: Segment Revenues (CHF Billion), FY 2014
  • Figure 10.6: Lonza: Potency Classification System
  • Figure 10.7: Novasep: Segment Revenues (EUR Million)
  • Figure 10.8: Pfizer CentreSource: Revenues, (USD Million), FY 2010 - FY 2014
  • Figure 10.9: Piramal Healthcare: Revenues (INR Billion), FY 2011 - H1 2016
  • Figure 10.10: Piramal Healthcare: Segment Revenues (INR Billion), FY 2015
  • Figure 11.1: Dr. Reddy Laboratories: Revenues (INR Billion), FY 2011 - H1 2016
  • Figure 11.2: Dr. Reddy's Laboratories: Segment Revenues (INR Billion), FY 2015
  • Figure 11.3: IDT Australia: Revenues (USD Million), FY 2010 - FY 2015
  • Figure 11.4: Intas Pharmaceuticals: Revenues (INR Billion), FY 2011 - FY 2015
  • Figure 12.1: Formosa Laboratories: Revenues (NTD Billion), FY 2012 - Q1 2015
  • Figure 12.2: OPKO Health: Revenues (USD Million), FY 2010 - H1 2015
  • Figure 12.3: ScinoPharm: Revenues (NTD Billion), FY 2010 - H1 2015
  • Figure 12.4: WuXi PharmaTech: Net Revenues (USD Million), FY 2010 - H1 2015
  • Figure 13.1: CMO Investments, 2006-2015: Distribution by Type of Investment
  • Figure 13.2: HPAPIs and Cytotoxic Drugs: Leading Players by Investments
  • Figure 13.3: HPAPIs and Cytotoxic Drugs: Distribution by Type of Partnership
  • Figure 13.4: HPAPIs and Cytotoxic Drugs: Deals and Partnerships, 2006 - 2015
  • Figure 17.1: HPAPIs and Cytotoxic Drugs Contract Manufacturing Market Forecast: 2016, 2021 and 2026 (USD Billion)

List of Tables

  • Table 3.1: APIs and HPAPIs: OEL
  • Table 3.2: Categorization of APIs: International Safety Systems
  • Table 3.3: SafeBridge: Categorization System
  • Table 3.4: Merck Categorization System
  • Table 3.5: Lonza Categorization System
  • Table 4.1: CMOs with HPAPI and Cytotoxic Drugs Production Facilities
  • Table 4.2: New Entrants in HPAPI and Cytotoxic Market
  • Table 4.3: Pharma Companies with In-house HPAPI and Cytotoxics Production Facilities
  • Table 4.4: US Guidelines for Handling Hazardous / Cytotoxic Drugs
  • Table 5.1: HPAPI: CMO Capability Analysis
  • Table 5.2: HPAPI CMOs: Analysis by OELs
  • Table 5.3: Aesica: Production Capacity
  • Table 5.4: Ajinomoto Omnichem: Production Capacity
  • Table 5.5: Helsinn: HPAPI Production Capacity
  • Table 5.6: Helsinn: Cytotoxic API Production Capacity
  • Table 6.1: Cytotoxic Drugs: CMOs Capability Analysis
  • Table 6.2: Cytotoxic Drugs CMOs: Analysis by Occupational Exposure Limits (OELs)
  • Table 6.3: Cytotoxic Drugs CMOs: Fill / Finish Capability Analysis
  • Table 6.4: Cytotoxic Drugs CMOs: Distribution by Packaging Form
  • Table 7.1: HPAPIs and Cytotoxic Drugs: Companies Providing One-Stop-Shop Services
  • Table 7.2: Baxter BioPharma Solutions: Facility Sites and Manufacturing Services
  • Table 7.3: CordenPharma: Production Facilities
  • Table 7.4: CordenPharma, Latina: Cytotoxic Drugs Production Capacity
  • Table 7.5: Excella: Highly Potent Drug Manufacturing Services' Capacity
  • Table 8.1: ADCs: Level of Outsourcing
  • Table 9.1: SAFC Commercial: Highly Potent Compound Facilities
  • Table 10.1: Helsinn: Cytotoxic Plant, Production Area Capabilities
  • Table 11.1: Intas Pharmaceuticals: Facility Sites & Functions
  • Table 12.1: Formosa Laboratories: High Potency Compounds Production Capability
  • Table 12.2: NerPharma DS: Manufacturing Suites Production Capability
  • Table 13.1: CMO Investments, 2006-2015
  • Table 13.2: HPAPIs and Cytotoxic Drugs: Deals and Partnerships, 2003-2015
  • Table 14.1: HPAPIs and Cytotoxic Drugs: SWOT Analysis
  • Table 15.1: List of Contract Manufacturers and Their Capabilities in ADC Manufacturing
  • Table 15.2: CMOs Offering ADC Conjugation Services
  • Table 15.3: Full Service Contract Manufacturers for ADCs
  • Table 18.1: HPAPI Production Facilities: Distribution by Scale of Operation
  • Table 18.2: HPAPI Production Facilities: Regional Distribution
  • Table 18.3: Cytotoxic Drugs Production Facilities: Distribution by Scale of Operation
  • Table 18.4: Cytotoxic Drugs Production Facilities: Regional Distribution
  • Table 18.5: AMRI Global: Contract Revenues (USD Million), FY 2010 - H1 2015
  • Table 18.6: AMRI Global: Segment Revenues (USD Million), FY 2014
  • Table 18.7: AMRI Global: Segment Contract Revenues (USD Million), H1 2014 & H1 2015
  • Table 18.8: Baxter BioPharma Solutions: Revenues (USD Million), FY 2011 - FY 2014
  • Table 18.9: Pierre Fabre Laboratories: Revenues (EUR Million), FY 2014
  • Table 18.10: Cytotoxic Drugs Sales Forecast, 2016 - 2026: Base Scenario (USD Billion)
  • Table 18.11: Cytotoxic Drugs Sales Forecast, 2016 - 2026: Conservative Scenario (USD Billion)
  • Table 18.12: Cytotoxic Drugs Sales Forecast, 2016 - 2026: Optimistic Scenario (USD Billion)
  • Table 18.13: Cytotoxic Drugs Contract Manufacturing Market, 2016 - 2026: Base Scenario (USD Billion)
  • Table 18.14: Cytotoxic Drugs Contract Manufacturing Market, 2016 - 2026: Conservative Scenario (USD Billion)
  • Table 18.15: Cytotoxic Drugs Contract Manufacturing Market, 2016 - 2026: Optimistic Scenario (USD Billion)
  • Table 18.16: Cytotoxic Drugs Contract Manufacturing Market: Regional Distribution, 2016, 2021 and 2026
  • Table 18.17: HPAPIs Contract Manufacturing Market, 2016 - 2026: Base Scenario (USD Billion)
  • Table 18.18: HPAPIs Contract Manufacturing Market, 2016 - 2026: Conservative Scenario (USD Billion)
  • Table 18.19: HPAPIs Contract Manufacturing Market, 2016 - 2026: Optimistic Scenario (USD Billion)
  • Table 18.20: HPAPIs Contract Manufacturing Market: Regional Distribution, 2016, 2021 and 2026
  • Table 18.21: AbbVie: Revenues (USD Billion), FY 2010 - H1 2015
  • Table 18.22: Catalent Pharma Solutions: Revenues (USD Billion), FY 2010 - Q1 2016
  • Table 18.23: Catalent Pharma Solutions: Segment Revenues (USD Million), FY 2015
  • Table 18.24: Evonik: Revenues (EUR Billion), FY 2010 - H1 2015
  • Table 18.25: Evonik: Segment Revenues (EUR Million), FY 2014
  • Table 18.26: Sigma-Aldrich: Revenues (USD Billion), FY 2010 - H1 2015
  • Table 18.27: Sigma-Aldrich: Segment Revenues (USD Million), FY 2014
  • Table 18.28: Sigma-Aldrich: Segment Revenues (USD Million), Q1 - Q3 2015
  • Table 18.29: SAFC Commercial: Revenues (USD Million)
  • Table 18.30: Dishman Group: Turnover (INR Billion), FY 2010 - H1 2016
  • Table 18.31: Dishman Group: Segment Revenues (INR Billion), FY 2015
  • Table 18.32: CARBOGEN AMCIS: Revenues (INR Billion), FY 2011 - FY 2015
  • Table 18.33: Lonza: Revenues, (CHF Billion), FY 2010 - H1 2015
  • Table 18.34: Lonza: Segment Revenues (CHF Million), FY 2014
  • Table 18.35: Novasep: Segment Revenues (EUR Million), FY 2013
  • Table 18.36: Pfizer CentreSource: Revenues, (USD Million) FY 2010 - H1 2015
  • Table 18.37: Piramal Healthcare: Revenues (INR Billion), FY 2011 - H1 2016
  • Table 18.38: Piramal Healthcare: Segment Revenues (INR Billion), FY 2015
  • Table 18.39: Dr. Reddy's Laboratories: Revenues (INR Billion), FY 2011 - H1 2016
  • Table 18.40: Dr. Reddy's Laboratories: Segment Revenues (INR Billion), FY 2015
  • Table 18.41: IDT Australia: Revenues (USD Million), FY 2010 - FY 2015
  • Table 18.42: Intas Pharmaceuticals: Revenues (INR Billion), FY 2011 - FY 2015
  • Table 18.43: Formosa Laboratories: Revenues (NTD Billion), FY 2012 - Q1 2015
  • Table 18.44: OPKO Health: Revenues (USD Million), FY 2010 - H1 2015
  • Table 18.45: ScinoPharm: Revenues (NTD Billion), FY 2010 - H1 2015
  • Table 18.46: WuXi PharmaTech: Net Revenues (USD Million), FY 2010 - H1 2015
  • Table 18.47: CMO Investments, 2006-2015: Distribution by Type of Investment
  • Table 18.48: HPAPIs and Cytotoxic Drugs: Leading Players by Investments
  • Table 18.49: HPAPIs and Cytotoxic Drugs: Distribution by Type of Partnership
  • Table 18.50: HPAPIs and Cytotoxic Drugs: Deals and Partnerships, 2006 - 2015
  • Table 18.51: HPAPI Contract Manufacturing Market (USD Billion) Forecast: 2016, 2021 and 2026
  • Table 18.52: Cytotoxic Drugs Contract Manufacturing Market (USD Billion) Forecast: 2016, 2021 and 2026

Listed Companies

The following companies and organizations have been mentioned in this report:

  • 1. AAIPharma Services Corp.
  • 2. AB SCIEX
  • 3. AbbVie
  • 4. ACES Pharma
  • 5. ADC Biotechnology
  • 6. Aenova Group
  • 7. Aesica Pharmaceuticals
  • 8. Affinity Lifesciences
  • 9. Agno Pharma
  • 10. Ajinomoto Omnichem
  • 11. Alkermes Contract Pharma Services
  • 12. ALMAC Group
  • 13. Alphora Research
  • 14. Amatsigroup
  • 15. AMPAC Fine Chemicals
  • 16. AMRI
  • 17. Aptuit
  • 18. Arch Pharmalabs
  • 19. Ash Stevens
  • 20. Aspen Holdings
  • 21. Asymchem Laboratories
  • 22. AVANTHERA
  • 23. Avecia
  • 24. AzayaTherapeutics
  • 25. Bachem
  • 26. Banner Pharmacaps
  • 27. Baxter BioPharma Solutions
  • 28. Bayer
  • 29. Bend Research
  • 30. BioAgilytix Labs
  • 31. BioOutsource
  • 32. Biopharma Technology
  • 33. Biotechnique
  • 34. Biotest
  • 35. BioVectra
  • 36. Boehringer Ingelheim
  • 37. Bristol Myers Squibb
  • 38. Bryllan
  • 39. BSP Pharmaceuticals
  • 40. Cadila Healthcare
  • 41. Cambrex
  • 42. Cambridge Major Laboratories
  • 43. Capsugel
  • 44. CARBOGEN AMCIS
  • 45. Catalent
  • 46. Cedarburg Pharmaceuticals
  • 47. Celldex Therapeutics
  • 48. Celon Labs
  • 49. Cerbios
  • 50. ChemCon
  • 51. ChemPartner
  • 52. ChemSun Pharmaceutical
  • 53. CMC Biologics
  • 54. Coland Holdings
  • 55. Coldstream Laboratories
  • 56. Concortis Biosystems
  • 57. CordenPharma
  • 58. Creapharm Parenterals
  • 59. Creative Biolabs
  • 60. Cytovance Biologics
  • 61. Dalton Pharma Services
  • 62. Dishman Group
  • 63. Dorizoe LifeSciences
  • 64. Dottikon Exclusive Synthesis
  • 65. Dr. Reddy's Laboratories
  • 66. DSM Pharmaceuticals
  • 67. EaglePicher Pharmaceutical Services
  • 68. EirGen Pharma
  • 69. EirGenix
  • 70. Eisai
  • 71. Eli Lilly
  • 72. EMD Serono
  • 73. Encap Drug Delivery
  • 74. Eucodis Bioscience
  • 75. Evonik
  • 76. Excella GmbH
  • 77. Fareva
  • 78. Farmabios
  • 79. Ferro Pfanstiehl
  • 80. FineTech Pharmaceuticals
  • 81. Foresee Pharmaceuticals
  • 82. Formex
  • 83. Formosa Laboratories
  • 84. Fresenius Kabi
  • 85. FUJIFILM Diosynth Biotechnologies
  • 86. Gadea Pharmaceutical Group
  • 87. Genentech
  • 88. GlaxoSmithKline
  • 89. Goodwin Biotechnology
  • 90. GP Pharm
  • 91. Granules
  • 92. Haupt Pharma
  • 93. Helsinn
  • 94. Heraeus Deutschland GmbH & Co. KG (Chemicals Division of Heraeus Group)
  • 95. Heraeus Precious Metals
  • 96. Hikal
  • 97. Hikma Pharmaceutical
  • 98. Hospira
  • 99. Holodiag
  • 100. Hovione
  • 101. iBIOSOURCE
  • 102. Icrom
  • 103. Idifarma
  • 104. IDT Australia
  • 105. ImmunoGen
  • 106. Immunomedics
  • 107. Indena
  • 108. Infa Group
  • 109. InSphero
  • 110. Intas Pharmaceuticals
  • 111. Intellect Neurosciences
  • 112. IRIX Pharmaceuticals (acquired by Patheon)
  • 113. Johnson & Johnson
  • 114. Johnson Matthey Pharma Services
  • 115. Kemwell
  • 116. KKR & Co.
  • 117. Kyongbo Pharmaceutical Co. Ltd
  • 118. Labochim SpA
  • 119. Lipocine
  • 120. Lonza
  • 121. Matrix Laboratories
  • 122. Mayne Pharmaceuticals
  • 123. Medichem
  • 124. MedImmune
  • 125. Merck Serono
  • 126. Mersana Therapeutics
  • 127. Metrics
  • 128. Micron Technologies
  • 129. Millennium Pharmaceuticals
  • 130. MI-mAbs
  • 131. Minafen
  • 132. Natco Pharma
  • 133. NerPharMa
  • 134. Nerviano Medical Sciences
  • 135. Neuland Laboratories
  • 136. NextPharma Technologies
  • 137. Nicholas Laboratories
  • 138. Normon
  • 139. Novartis
  • 140. Novasep
  • 141. Nycomed Amersham
  • 142. Oasmia Pharmaceutical
  • 143. Olon S.p.A.
  • 144. Omni Chem
  • 145. One2One (Hospira)
  • 146. OPKO Health
  • 147. Organichem
  • 148. OsoBio
  • 149. Pacific GMP
  • 150. Patheon
  • 151. Penn Pharma
  • 152. Pfanstiehl
  • 153. Pfizer CentreSource
  • 154. Pharmascience
  • 155. Pharmatek
  • 156. Pierre Fabre Medicament Production
  • 157. Piramal
  • 158. Polymun Scientific
  • 159. Polytherics
  • 160. Powder Systems Limited
  • 161. Prasfarma
  • 162. Priaxon
  • 163. Procos
  • 164. Progenics Pharmaceuticals
  • 165. ProJect Pharmaceutics
  • 166. QPS Holdings
  • 167. QS Pharma
  • 168. Quanta BioDesign
  • 169. Ranbaxy Laboratories
  • 170. Redwood Biosciences
  • 171. Regis Technologies
  • 172. Roche
  • 173. Rottendorf Pharma GmbH
  • 174. Sigma Aldrich Fine Chemicals
  • 175. Sandoz
  • 176. Sanofi Aventis
  • 177. ScinoPharm
  • 178. SCM Pharma
  • 179. Seattle Genetics
  • 180. Serina Therapeutics
  • 181. Siegfried
  • 182. Spirogen
  • 183. Stason Pharmaceuticals
  • 184. Sumitra Pharmaceuticals
  • 185. Sun European Partners
  • 186. Sundia Meditech
  • 187. Symbiosis Pharmaceutical Services
  • 188. Syntagon
  • 189. Syn-the-All Pharmaceutical Co. Ltd. (STA)
  • 190. Synthon Biopharmaceuticals
  • 191. TAPI
  • 192. Tetrionics
  • 193. The Chemistry Research Solution
  • 194. Transporin
  • 195. TUBE Pharma
  • 196. Uman Pharma
  • 197. UPM Pharmaceuticals
  • 198. Vianex S.A.
  • 199. Vion Pharmaceuticals
  • 200. VUAB Pharma (acquired Brno plant in 2010)
  • 201. VxP Pharmaceuticals
  • 202. Waters
  • 203. Wuxi Pharma
Back to Top